Psychedelics startup Gilgamesh has no interest in psilocybin or LSD
It’s developing new compounds and attracting investors
Published in
8 min readMar 9
--
Many startup companies developing psychedelic therapies work with classic mind-altering substances such as psilocybin, mescaline and LSD. Jonathan Sporn, the founder and chief executive of Gilgamesh Pharmaceutical, has no interest in any of them.
